AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1560699
Drug: Topical 40%
RxNorm normalized name: urea topical 40% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 40% idoxuridine in dimethyl sulfoxide (IDU)
Trial: 3840882
Drug: Intravenous furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous furosemide (2 mg/kg)
Trial: 3840882
Drug: Inhaled atropine
RxNorm normalized name: atropine sulfate Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled atropine sulfate (0.05 mg/kg)
Trial: 3840882
Drug: Inhaled isoproterenol
RxNorm normalized name: isoproterenol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled isoproterenol (0.2 cc, 1:200)
Trial: 23075634
Drug: Alfentanil and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil and morphine (Group AM)
Trial: 17713162
Drug: TMC125 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC125 100 mg twice daily coadministered with DRV/r 600/100 mg twice daily
Trial: 17713162
Drug: TMC125 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC125 200 mg twice daily coadministered with DRV/r 600/100 mg twice daily
Trial: 17713162
Drug: DRV/r 600/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV/r 600/100 mg twice daily
Trial: 15053373
Drug: Salbutamol alone
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol alone (0.03 ml/kg/dose)
Trial: 15053373
Drug: Combined nebulization
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined nebulization of Salbutamol (0.03 ml/kg/dose) and Ipratropium bromide (250 microgm/dose for three doses)
Trial: 11575732
Drug: Treatment algorithms
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment algorithms for treatment-resistant depression
Trial: 11575732
Drug: Texas Medication
RxNorm normalized name: influenza A virus A/Texas/50/2012 (H3N2) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Texas Medication Algorithm Project
Trial: 11575732
Drug: Sequenced Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequenced Treatment Alternatives to Relieve Depression
Trial: 9337491
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment package including cognitive correction, problem-solving training, social skills training, and relapse prevention
Trial: 3035003
Drug: Anti-D immunoglobulin
RxNorm normalized name: Anti-D immunoglobulin
DrugBank: Human Rho(D) immune globulin (DB11597)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-D immunoglobulin injections at 28th and 34th weeks of pregnancy
Trial: 3035003
Drug: Antepartum treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antepartum treatment
Trial: 25596910
Drug: CONSORT dosing
RxNorm normalized name: AVOBENZONE 28.5 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTINOXATE 70 mg in 1 mL / OCTISALATE 30 mg in 1 mL / OCTOCRYLENE 90 mg in 1 mL TOPICAL CREAM [Pur Confort SPF 15]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CONSORT dosing (follitropin alfa starting dose determined by the CONSORT calculator)
Trial: 25596910
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing (150 IU of follitropin alfa)
Trial: 21955647
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg genistein
Trial: 21955647
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg pure S-(−)equol
Trial: 21955647
Drug: Soy infant
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy infant formula and soy germ isoflavone supplement
Trial: 9446300
Drug: Infrared pulsed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infrared pulsed laser therapy
Trial: 1526696
Drug: Zolpidem 10
RxNorm normalized name: zolpidem 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 10 mg and 20 mg
Trial: 3886706
Drug: tolmetin 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolmetin 1,200 mg/d for three weeks
Trial: 25517279
Drug: Grape powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape powder (500 mg of polyphenols/day)
Trial: 14529097
Drug: Montelukast (5-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (5-mg chewable tablet once daily)
Trial: 14529097
Drug: Cromolyn (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cromolyn (two puffs 4 times daily)
Trial: 10634360
Drug: Testosterone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (300 mg, im, every 3 weeks)
Trial: 10634360
Drug: NRTI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRTI treatment without protease inhibitor
Trial: 10634360
Drug: NRTI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRTI treatment with protease inhibitor
Trial: 9336129
Drug: Standard radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard radiation therapy with 60 Gy at 2.0 Gy per day (STD RT)
Trial: 9336129
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with cisplatin 100 mg/m2 days 1 and 29 with vinblastine 5 mg/m2 weekly for 5 weeks followed by 60 Gy at 2.0 Gy per day (CT + RT)
Trial: 9336129
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation therapy with 69.6 Gy at 1.2 Gy b.i.d. (HFX RT)
Trial: 8441078
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tests (palpation or percussion)
Trial: 2876325
Drug: Pneumococcal capsular
RxNorm normalized name: pneumococcal capsular polysaccharide type 1 vacc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal capsular polysaccharide vaccines
Trial: 24218527
Drug: IFNB1b 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNB1b 250 μg subcutaneously every other day
Trial: 22354108
Drug: Manual-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual-assisted therapy (MAT)
Trial: 18208849
Drug: Perfusion-cardiac magnetic
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perfusion-cardiac magnetic resonance (perfusion-CMR) at a dose of 0.1 mmol/kg Gd-DTPA-BMA
Trial: 15931612
Drug: Beef supplementation
RxNorm normalized name: Beef
DrugBank: Beef (DB10509)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beef supplementation (0.6 g-protein/kg per day)
Trial: 12839376
Drug: Azathioprine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (2.5 mg/Kg/day; Group A, n = 12)
Trial: 12839376
Drug: Sulfasalazine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (6 g/day; Group B, n = 13)
Trial: 7473798
Drug: TRH (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRH (0.2 mg/kg intravenous bolus followed by 0.2 mg/kg/h infusion over 6 h)
Trial: 2075851
Drug: High-dose addicts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose addicts
Trial: 2075851
Drug: Low-dose addicts
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose addicts
Trial: 7053242
Drug: Ceftriaxone 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 150 mg
Trial: 7053242
Drug: Ceftriaxone 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1500 mg
Trial: 6368591
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose chenodiol (750 mg/d)
Trial: 6368591
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose chenodiol (375 mg/d)
Trial: 20804443
Drug: Technosphere Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Technosphere Insulin (TI), single 30-U dose
Trial: 18754845
Drug: Pre-HD folic
RxNorm normalized name: Pre Folic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-HD folic acid (5 mg) administration
Trial: 18754845
Drug: Intra-HD folic
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-HD folic acid (5 mg) administration
Trial: 12876164
Drug: Long term
RxNorm normalized name: BENZETHONIUM CHLORIDE 0.12 g in 100 mL TOPICAL SOLUTION [CA-REZZ - LONG TERM CARE - INCONTINENT CLEANSER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long term antibiotics
Trial: 12876164
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (surgery and antibiotics)
Trial: 1342209
Drug: Nitrendipine plus
RxNorm normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine plus ranitidine (300 mg, 150 mg twice a day)
Trial: 3859359
Drug: CRT +
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CRT + ITC (induction intrathecal chemotherapy and cranial irradiation plus maintenance ITC)
Trial: 3859359
Drug: CSpRT (induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSpRT (induction intrathecal chemotherapy and craniospinal irradiation with no maintenance ITC)
Trial: 26824884
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily hydromorphone (HOD)
Trial: 26824884
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily hydromorphone (HTD)
Trial: 24850606
Drug: rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 10 mg with UDCA
Trial: 20669672
Drug: Tetramethylpyrazine (TMP)
RxNorm normalized name: Tetramethylpyrazine
DrugBank: Ligustrazine (DB19074)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetramethylpyrazine (TMP) 240 mg/d added to conventional treatment for 10-14 days
Trial: 20669672
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (Piperacillin, Levofloxacin, Ambroxol, Doxofylline)
Trial: 18510632
Drug: Alemtuzumab induction
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab induction followed by delayed tacrolimus monotherapy
Trial: 18510632
Drug: Tacrolimus in
RxNorm normalized name: tacrolimus Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus in combination with mycophenolate mofetil and steroids
Trial: 1478392
Drug: Aerobic training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerobic training program (thrice weekly for 8 weeks, starting at 40% of maximal oxygen uptake)
Trial: 28811107
Drug: Intraoperative periarticular
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative periarticular injection with added morphine (0.1 mg/kg)
Trial: 28811107
Drug: Intraoperative periarticular
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative periarticular injection without added morphine
Trial: 8844450
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg three times a day for 16 days
Trial: 1614087
Drug: 0.1% dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% dexamethasone and antibiotics (first trial)
Trial: 1614087
Drug: Antibiotics without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotics without steroids (first trial)
Trial: 1614087
Drug: 0.1% dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% dexamethasone 4x daily (second trial)
Trial: 1614087
Drug: 0.1% dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% dexamethasone 4x daily for 5 days, then 1x daily (second trial)
Trial: 1614087
Drug: 0.1% dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% dexamethasone 1x daily (second trial)
Trial: 30325583
Drug: Sarpogrelate 100-mg
RxNorm normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarpogrelate 100-mg tablets under fasting conditions
Trial: 30325583
Drug: Sarpogrelate 100-mg
RxNorm normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarpogrelate 100-mg tablets under fed conditions
Trial: 29247820
Drug: Local anesthesia
RxNorm normalized name: Esters of benzoic acid for local anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia (various agents and techniques)
Trial: 29247820
Drug: Different anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different anesthetic techniques and drug subgroups
Trial: 26429522
Drug: Tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg for 1 week
Trial: 23052890
Drug: Therapeutic hypothermia
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic hypothermia (TH) with an individual target range temperature between 34 and 35 °C administered for 24 hours
Trial: 19914974
Drug: H(2) antagonists
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: H(2) antagonists
Trial: 17391558
Drug: DHA-rich fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich fish oil (6 g/d; about 2 g n-3 PUFA; 1.6 g DHA/d)
Trial: 17391558
Drug: Sunflower oil
RxNorm normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower oil (6 g/d, placebo)
Trial: 17391558
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of moderate exercise and fish-oil supplementation
Trial: 17391558
Drug: Exercise and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise and oil combination
Trial: 15467102
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (20 g x d(-1) Cr + 140 g x d(-1) glucose polymer)
Trial: 15467102
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (responders with increased intramuscular Cr levels)
Trial: 2253907
Drug: Famotidine infusion
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Famotidine infusion after 10 mg bolus
Trial: 2253907
Drug: Famotidine infusion
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Famotidine infusion alone
Trial: 31944250
Drug: Parent-administered exercise
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-administered exercise program (10 minutes twice a day for 3 weeks)
Trial: 31944250
Drug: Parent-administered exercise
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-administered exercise program
Trial: 30958348
Drug: 20 IU
RxNorm normalized name: Calcium/Phosphorus/Vitamin D 105 MG-81 MG-120 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 IU intranasal insulin
Trial: 23907764
Drug: 40 IU
RxNorm normalized name: Oxytocin 40 IU/1 ML Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 IU intranasal insulin
Trial: 24393856
Drug: Colorectal cancer-specific
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colorectal cancer-specific peptide vaccines (RNF43, TOMM34) with uracil/tegafur (UFT) + Leucovorin (LV)
Trial: 24393856
Drug: Colorectal cancer-specific
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colorectal cancer-specific peptide vaccines (RNF43, TOMM34)
Trial: 24393856
Drug: Vaccines against
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccines against multiple peptides (RNF43, TOMM34, FOXM1, MELK, HJURP, VEGFR1, VEGFR2)
Trial: 21765371
Drug: Intravitreal diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal diclofenac (500 μg/0.1 mL)
Trial: 21765371
Drug: Intravitreal triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal triamcinolone (4 mg/0.1 mL)
Trial: 16671073
Drug: Bilateral subthalamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral subthalamic nucleus deep brain stimulation (B‐STN DBS) plus medication
Trial: 31802059
Drug: EVOO therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVOO therapy
Trial: 31802059
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (MCI without therapy)
Trial: 24401516
Drug: Ventralex Hernia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventralex Hernia Patch (Bard USA)
Trial: 12231575
Drug: AHA diet
RxNorm normalized name: AHA
DrugBank: Acetohydroxamic acid (DB00551)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AHA diet + simvastatin (20 mg daily)
Trial: 31418121
Drug: 200 g
RxNorm normalized name: PEG-200 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 g rice with 4 g dried wakame
Trial: 31418121
Drug: 200 g
RxNorm normalized name: PEG-200 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 g rice
Trial: 21329988
Drug: Fluoxetine 20mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20mg/day plus celecoxib 400mg/day (200mg BID)
Trial: 21329988
Drug: Fluoxetine 20mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20mg/day plus placebo
Trial: 18789466
Drug: Anti-Giardia and
RxNorm normalized name: Giardia lamblia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-Giardia and anthelminthic treatment
Trial: 18789466
Drug: Anti-Giardia treatment
RxNorm normalized name: Giardia lamblia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-Giardia treatment only
Trial: 17721622
Drug: tinzaparin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tinzaparin at 175 IU/kg, subcutaneous once daily, along with supportive care including morphine analgesia
Trial: 15487811
Drug: Nisolone (test)
RxNorm normalized name: triamcinolone diacetate Injectable Suspension [Cinolone]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisolone (test) tablets
Trial: 15487811
Drug: Delta‐Cortef (reference)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delta‐Cortef (reference) tablets
Trial: 7923797
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose transdermal estrogen (Estraderm TTS 25 micrograms) + oral progestogen (Duphaston 10 mg, 10 days every month) + daily exercise (walking for 1 hour)
Trial: 3301517
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg isosorbide dinitrate
Trial: 28668524
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 μg/kg/h)
Trial: 27453154
Drug: Biofeedback software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback software on a novel tablet computer platform
Trial: 26147154
Drug: OBV/PTV/r (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBV/PTV/r (25 mg/150 mg/100 mg) for 12 weeks (group A)
Trial: 12809957
Drug: Cyclobenzaprine 5
RxNorm normalized name: cyclobenzaprine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclobenzaprine 5 mg TID
Trial: 12809957
Drug: Cyclobenzaprine 10
RxNorm normalized name: cyclobenzaprine 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclobenzaprine 10 mg TID
Trial: 12809957
Drug: Cyclobenzaprine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclobenzaprine 2.5 mg TID
Trial: 10768448
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with progenitor-cell rescue
Trial: 9275441
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of oxytocin (control group)
Trial: 6378245
Drug: Diluted and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluted and undiluted topical corticosteroid preparations
Trial: 27314121
Drug: Roughened implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roughened implants
Trial: 21904901
Drug: lamotrigine (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lamotrigine (target dose 400 mg/day)
Trial: 17440020
Drug: Monofluorophosphate (MFP)
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monofluorophosphate (MFP) 20 mg/d
Trial: 11589718
Drug: Loop diuretic
RxNorm normalized name: Loop diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loop diuretic (LD; bumetanide)
Trial: 11589718
Drug: Thiazide diuretic
RxNorm normalized name: Thiazide diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide diuretic (TD; bendroflumethiazide)